Home

PONOI CAPITAL, LP

CIK 1707230 · last filed 2023-01-12

PONOI CAPITAL, LP is a corporate insider who has filed 13 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing shows the insider bought $14.8M of NGM on Jan 12, 2023. Across all open-market trades the lifetime net is +$92.5M, making them a net buyer over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

13

Lifetime Open-Market Net

$92.51M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NGM BIOPHARMACEUTICALS INC (NGM) Delisted 10%+ Owner 11,583,875 $1.54 $17.84M $79.61M 8 2023-01-12
RAPT Therapeutics, Inc. (RAPT) Delisted 10%+ Owner 175,251 $58.01 $10.17M -$91.40M 2 2021-09-16
CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted 10%+ Owner 4,159,186 $33.99 $141.37M $104.30M 3 2021-02-19

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-01-12 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +3,090,700 $14.79M EDGAR
2022-06-06 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +342,000 $4.46M EDGAR
2022-06-02 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +1,538,060 $20.70M EDGAR
2022-05-19 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +1,516,990 $20.22M EDGAR
2021-09-16 RAPT Therapeutics, Inc. (RAPT) Delisted Sell (S) −1,812,110 -$67.07M EDGAR
2021-09-03 RAPT Therapeutics, Inc. (RAPT) Delisted Sell (S) −688,500 -$24.33M EDGAR
2021-02-19 CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted Sell (S) −100,000 -$3.70M EDGAR
2020-12-16 CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted Exer (X) +301,070 $466.7K EDGAR
2020-08-31 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +624,940 $11.14M EDGAR
2020-07-23 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Mixed +241,930 $3.24M EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.